Generic Synthroid Approval Relies On Abbott Bioequivalence Methodology, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA rejects Abbott’s critique of its bioequivalence methodology and denies citizen petitions to stay levothyroxine generics. Methods used in approving NDAs should be acceptable for generic approvals, FDA says.